---
document_datetime: 2024-07-12 14:08:27
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sirturo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: sirturo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.266315
conversion_datetime: 2025-12-30 00:56:21.20189
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SIRTURO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                          |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------|
| II/0056              | Extension of indication (by removing the restriction limiting the use of Sirturo for patients for whom an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability) based on final results from study STREAM Stage 2; a multicentre, open-label, parallel-group, randomised, | 25/04/2024                          | 17/06/2024                                  | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-0056' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | active-controlled study in participants aged 15 years or older with RR/MDR-TB to evaluate an investigational BDQ-containing, all-oral, 40-week regimen of anti-TB drugs (Regimen C) compared to an injectable-containing 40-week control regimen (Regimen B). Submission of the study fulfils SOB 007. As a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. A revised RMP version 10.2 has been approved. Furthermore, the PI is brought in line with the latest QRD template version 10.3. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             |                                                                               |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------|
| PSUSA/10074 /202309 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11/04/2024 | n/a        |             | PRAC Recommendation - maintenance                                             |
| R/0054              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/10/2023 | 20/11/2023 |             |                                                                               |
| PSUSA/10074 /202303 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/09/2023 | n/a        |             | PRAC Recommendation - maintenance                                             |
| PSUSA/10074 /202209 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/04/2023 | n/a        |             | PRAC Recommendation - maintenance                                             |
| II/0051             | Update of section 4.6 of the SmPC in order to update information on breastfeeding based on new literature. In addition, the MAH took the opportunity to update the list of local representatives in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/02/2023 |            | SmPC and PL | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|             | Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0050      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/11/2022 | 20/12/2022 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0049/G   | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 06/05/2022 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10074 | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/04/2022 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| /202109   | bedaquiline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0045    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/11/2021 | 06/01/2022 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0048   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/12/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0043   | Update of section 4.2 of the SmPC to revise the information on the use of bedaquiline in combination with other medicinal products and to amend the information regarding treatment duration. In addition, the MAH took the opportunity to include an editorial correction in section 5.1 of the SmPC and to update the contact details for the local representative for UK in the package leaflet, in line with QRD version 10.2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/10/2021 | 15/11/2021 | SmPC and PL | The CHMP endorsed the following updates to the Product Information: Consideration should be given to WHO guidelines when selecting the appropriate combination regimen. Only use SIRTURO in combination with other medicinal products to which the patient's MDR-TB isolate has been shown to be susceptible in vitro, or is likely to be susceptible. The total duration of treatment with SIRTURO is 24 weeks. Data on longer treatment duration is very limited. When treatment with SIRTURO is considered necessary beyond 24 weeks to obtain a curative treatment, a longer duration of therapy may be considered under close safety surveillance. For more information, please refer to the Summary of |
| IAIN/0046 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                                                                                                       | 21/09/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0044   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/09/2021 | 15/11/2021 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10074 /202009 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                    | 09/04/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| X/0036/G            | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 28/01/2021 | 26/03/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0042             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                | 11/02/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0040              | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 12/11/2020 | 11/01/2021 | Annex II                         | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion |
| PSUSA/10074 /201909 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                    | 17/04/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0039             | C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                             | 08/04/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0038             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required      | 13/02/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0033/G           | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 12/12/2019 | 23/01/2020 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0035              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                             | 14/11/2019 | 09/01/2020 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10074 /201809 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                           | 14/03/2019 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0028             | C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH   | 14/02/2019   | 09/01/2020   | SmPC and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0031              | Renewal of the marketing authorisation.                                                                                                                                                                                                  | 15/11/2018   | 11/01/2019   |               | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0030             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                      | 13/12/2018   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0032              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                         | 12/10/2018   | 11/01/2019   | PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10074 /201709 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                | 12/04/2018   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0027/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                              | 04/04/2018   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|        | manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0024 | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/01/2018 | 05/03/2018 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional marketing authorisation for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. The CHMP also agreed that the changing treatment landscape has prompted changes to the timelines in providing the interim results and ultimately final study report of the phase III STREAM study (specific obligation) to Q4 2023. In addition, the MAH took the opportunity to bring the SmPC, labelling and package leaflet in line with the QRD template version 10.0; and update the local representative in Lithuania and Slovenia. |

<div style=\"page-break-after: always\"></div>

| II/0026             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                  | 08/02/2018   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10074 /201703 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                      | 28/09/2017   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0021             | Update of section 4.4 of the SmPC in order to add delamanid and levofloxacin as examples of drugs that prolong the QT interval following the review of the global safety database for all serious cases received from 28 December 2012 to 30 September 2016. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 29/06/2017   | 05/03/2018 | SmPC and PL | The cumulative review of QT prolongation events with the use of bedaquiline (BDQ) from 28 December 2012 to 30 September 2016 suggest that when co administered with other medicinal products that prolong the QTc interval (including delamanid and levofloxacin), an additive or synergistic effect on QT prolongation cannot be excluded. Caution is recommended when prescribing bedaquiline concomitantly with medicinal products with a known risk of QT prolongation. In the event that co administration of such medicinal products with bedaquiline is necessary, clinical monitoring including frequent electrocardiogram assessment is recommended. Section 4.4 of the SmPC under 'Cardiovascular safety' was updated accordingly. |
| PSUSA/10074 /201609 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                      | 21/04/2017   | 16/06/2017 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10074/201609.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0022             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                               | 28/04/2017   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0017              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                        | 10/11/2016   | 23/12/2016 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                              |            |            |                    | opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0020             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                             | 22/12/2016 | n/a        |                    |                                                                                                                                                                                                                                                                                                       |
| IB/0018             | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                      | 09/11/2016 | 23/12/2016 | SmPC and Labelling |                                                                                                                                                                                                                                                                                                       |
| PSUSA/10074 /201603 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                    | 29/09/2016 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                     |
| N/0015              | Update of the package leaflet with revised contact details of the local representatives for Estonia, Lithuania, Latvia, Romania and Sweden. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 22/04/2016 | 23/12/2016 | PL                 |                                                                                                                                                                                                                                                                                                       |
| PSUSA/10074 /201509 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                    | 17/03/2016 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                     |
| IB/0014             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                    | 19/02/2016 | 23/12/2016 | SmPC               |                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IB/0013   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                 | 07/01/2016   | 23/12/2016   | SmPC, Annex II, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0010    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/11/2015   | 07/01/2016   |                                    | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.                                                                                                                      |
| IA/0012/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                  | 22/12/2015   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0008/G | This was an application for a group of variations. Update of sections 5.1 and 5.2 of the SmPC in order to update information on mechanisms of resistance and drug-drug interactions of bedaquiline based on the results from non-clinical studies. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, minor editorial changes have been introduced throughout the PI. | 22/10/2015   | 07/01/2016   | SmPC and PL                        | In this variation the MAH updated the Product Information with data related to the mechanisms of resistance. Target- based mutations generated in preclinical studies lead to 8- to 133 fold increases in bedaquiline MIC, resulting in MICs ranging from 0.25 to 4.0 mg/l. Efflux-based mutations have been seen in preclinical and clinical isolates. These lead to 2- to 8 fold increases in bedaquiline MICs, resulting in bedaquiline MICs ranging from 0.25 to 0.50 mg/l. However no clear relationship between increased post-baseline bedaquiline MICs and microbiologic outcomes was observed |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                       |            |            |                        | in the phase 2 trials where bedaquiline was given for 24 weeks, followed by continuation of the background regimen. Furthermore the MAH included the information from in vitro study which indicated a potential for bedaquiline to inhibit BCRP at the concentrations achieved in the intestine after oral administration. The clinical relevance is unknown.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10074 /201503 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                                 | 08/10/2015 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                |
| IB/0007/G           | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside | 30/04/2015 | 07/01/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10074 /201409 | Periodic Safety Update EU Single assessment - bedaquiline                                                                                                                                                                                                                                                                                                                                 | 10/04/2015 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                |
| IG/0531             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                        | 05/03/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                  |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                   | 20/11/2014 | 19/01/2015 |                        | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           |                                                    |            |            |          | opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for SIRTURO, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.   |
|-----------|----------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002/G | This was an application for a group of variations. | 18/12/2014 | 07/01/2016 | SmPC and |                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |           |      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|------|
| II/0004/G | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                                   | 20/11/2014 | 19/01/2015 | SmPC      | data |
| N/0001    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/03/2014 | 19/01/2015 | Labelling |      |